ATAI Life Sciences BV (ATAI)vsModerna Inc (MRNA)
ATAI
ATAI Life Sciences BV
$7.35
0.00%
HEALTHCARE · Cap: $2.70B
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 49721% more annual revenue ($2.23B vs $4.47M). ATAI leads profitability with a 0.0% profit margin vs -141.4%. ATAI earns a higher WallStSmart Score of 28/100 (F).
ATAI
Avoid28
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.8%
Fair Value
$10.66
Current Price
$7.35
$3.31 discount
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 137.0% year-over-year
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Trading at 15.3x book value
0.0% margin — thin
ROE of -378.0% — below average capital efficiency
Earnings declined 96.8%
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ATAI
The strongest argument for ATAI centers on Revenue Growth, Debt/Equity. Revenue growth of 137.0% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ATAI
The primary concerns for ATAI are Price/Book, Profit Margin, Return on Equity.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ATAI profiles as a hypergrowth stock while MRNA is a turnaround play — different risk/reward profiles.
ATAI carries more volatility with a beta of 1.55 — expect wider price swings.
ATAI is growing revenue faster at 137.0% — sustainability is the question.
ATAI generates stronger free cash flow (-35M), providing more financial flexibility.
Bottom Line
ATAI scores higher overall (28/100 vs 21/100) and 137.0% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ATAI Life Sciences BV
HEALTHCARE · BIOTECHNOLOGY · USA
ATAI Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?